[Dec, 2018] The global antibiotic resistance market size is estimated to reach USD 12.07 billion by 2025. It is anticipated to post a CAGR of 5.6% during the forecast period.
Request A Sample Copy of this Market Report @: http://bit.ly/2Rbgwke
Rising burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens has been driving the market. Biotech companies that are developing therapies for antibiotic-resistant infections include Melinta Therapeutics, Achaogen, and Nabriva Therapeutics. On the other hand, majority of large pharmaceutical companies don't find this market lucrative enough due to slower growth in revenues for marketed drugs and lower return on investments. For instance, Novartis recently discontinued development of its antibacterial drugs for antibiotic resistance. Manufacturers can obtain the Qualified Infectious Disease Product (QIDP) designation, which escalates the clinical review process for antibacterial therapies targeting high priority pathogens. The QIDP designation enables faster access to targeted agents and was introduced under the GAIN (Generating Antibiotic Incentives Now) Act, passed in 2012 as an extension to the U.S. FDA Safety and Innovation Act. The legislation aims to encourage the development of novel therapies for growing burden and severity of infections with antibiotic resistance.
Further key findings from the report suggest:
• In 2017, the market by cUTI disease registered significant sales due to elevated rate of resistance in extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae and P. aeruginosa strains
• The combination therapies segment, which includes fixed-dose combinations of beta lactams and beta lactamase inhibitors, is projected to witness the fastest growth rate over the forecast period
• Infections due to E. coli pathogens that are ESBL-producing and carbapenem-resistant led in terms of sales revenue in 2017 due to high treatment cost
• On the geographical front, North America was the dominant revenue contributor in the market in 2017. Improving reimbursement scenario with new technology add-on payment provision is promoting the use of novel products in this region
• Among pharmaceutical companies, Merck, Allergan, and Pfizer were the key players with top-selling drugs in the antibiotic resistance market in 2017.
Browse Full Research Report of this Market With TOC @: http://bit.ly/2RhTmsF
Table of Contents:
Chapter 1 Report Scope
1.1 Segment Market Scope
1.2 Regional Scope
1.3 Estimates & Forecast Timeline
Chapter 2 Research Methodology
2.1 Model Details
2.1.1 Regression and variable analysis
2.2 Information Procurement
2.2.1 List of secondary sources
2.3 List of Primary Sources
2.4 Purchased database:
2.5 GVR's internal database
2.6 Primary interview breakup
2.6.1 Data for primary interviews, by sources
2.6.2 Data for primary interviews, by region
Chapter 3 Report Objectives
3.1 Objectives
Chapter 4 Executive Summary
4.1 Market Summary
Continued...
Explore Other Reports of this category By Radiant Insights,Inc at: https://www.radiantinsights.com/catalog/healthcare
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: [email protected]